Competing interests
Funding for this research was provided by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (MSD). The protocol was developed by NRG Oncology. MSD had a role in the current data analysis, the decision to publish and manuscript review. R.N.E. received institution research support from AstraZeneca, Clovis Oncology, Eisai, MSD and Novocure; consulting and advisory fees from AstraZeneca, Cardiff Oncology, Clovis Oncology, Eisai, Elevar Therapeutics, GSK/Tesaro, ImmunoGen, Inc., Seagen, Mersana, Myriad, Daichi Sankyo, PMV, Gilead, Onconova, Elevar Therapeutics and Regeneron along with personal payments for lectures and presentations from AstraZeneca, GSK, Immunogen, Merck, Medscape, Curio Biosciences, Great Debates and Updates. Additionally, R.N.E. serves in a leadership role as GOG Associate Clinical Trial Advisor as well as Scientific and Medical Advisor to the Clearity Foundation. M.W.S. reports receiving support from his employer, the Roswell Park Comprehensive Cancer Center with support from the National Cancer Institute as the government agency that funds the research. M.W.S. also acknowledges receiving support to attend meetings and travel R.G.M. received consulting fees from Fujirebio Diagnostics, Inc. F.B.M. received institutional support for clinical trials from GSK, Clovis, Immunogen, AstraZeneca, Seagen, Duality Bio, Acrivon, Allarity and Adaptimune, as well as consulting fees from the advisory boards of AstraZeneca, GSK, Daiichi Sankyo, BioNTech, Aadi. Consulting fees were also received from GSK and Seagen and an additional speaker fee from MSD. F.B.M. paritcipated on advisory boards for AstraZeneca, GSK, Daiichi Sankyo, BioNTech and Aadi and also reports serving on the Board of Directors for the Society of Gynecologic Oncology (unpaid) as well as on the Board of Directors for the Rivkin Foundation (uncompensated). R.S.M. serves on the NRG Board of Directors for which his Institution receives compensation. M.S.S. receives consulting fees and honoraria from GSK, AstraZeneca, Merck and Immunogen and also serves as a board member for Unite for HER, a non-profit organization. E.G. served on an advisory board for Merck. E.L. received a grant from the Rhode Island Foundation. J.K. reports that US$300 was paid to their institution, Kaiser Permanente, in March 2023 for a lecture to the Association of Northern California Oncologists (ANCO) as well as receiving hotel expenses for this meeting. J.K. participated on an advisory board for a mirvetuximab study and approximately US$600 was paid to the institution in May 2022. C.A.L. received research funding for their institution and personal consulting fees, honorarium and international travel expenses from Merck. L.T.G. was paid consulting fees from Merck and GSK and also paid honoraria by AstraZeneca as a speaker. E.M.H. received consulting fees from AbbVie/Immunogen. L.M.L. received consulting fees for her participation on GlaxoSmithKline’s advisory board. Research grants were paid to the institution of F.B. from Merck, Eisai, ImmunoGen, Clovis, Beigene, Natera, Tempus and AstraZeneca while personal fees were also obtained from UptoDate and advisory boards (personal fees) were received from Agenus, Merck, Clovis, Immunogen, Eisai, AstraZeneca, GlaxoSmithKline, Myriad, BioNTech, Daiichi Sankyo, EMD Serono. Personal fees were also received by F.B. for CME lectures from Clinical Educational Concepts, Clinical Care Options, Medscape/WebMD, Med Learning, I3Health, CMR Institute, Global Learning Initiative/Prova, OncLive, Targeted Oncology, Research to Practice, GOG Foundation. GlaxoSmithKline and BioNTech provided support for F.B. to attend meetings and travel. F.B. holds uncompensated leadership roles on the Society of Gynecologic Oncology Board Member as a Co-Chair; NRG Oncology Developmental Therapeutic as a committee member and IGCS Education 360 as a Co-Chair. R.E.O.C. had support for this paper from NCI/NIH (P30CA008748). Grants were paid to R.E.O.C.’s institution from Bayer/Celgene/Juno, Arsenalbio, Tesaro/GSK, Merck, Ludwig Cancer Institute, AbbVie/StemCentrx, Regeneron, TCR2 Therapeutics, Atara Biotherapeutics, Inc., Marker Therapeutics, Syndax Pharmaceuticals, Genmab/Seagen Therapeutics, Genentech, Alkermes/Mural Oncology, Kite Pharma, Acrivon, OnCusp Therapeutics, and Gynecologic Oncology Foundation and the Lyell Immunopharma. R.E.O.C. also received payment and honoraria (one-off lectures) from GSK, Curio/Onclive/PER/MJH/Aptitude Health; SITC; Gynecologic Oncology Canada along with support for attending meetings from Hitech Health; Gathering Around Cancer, Ireland; GOG Foundation and SGO. In addition, R.E.O.C. served in an unpaid capacity for the Steering Committee for AstraZeneca (DUO-0), GSK (Moonstone, Prima) and Acrivon, as well as an unpaid advisor for Carina Biotech and Link Therapeutics. Furthermore, R.E.O.C. was an advisor to OnCusp Therapeutics and served on advisory boards for Tesaro/GSK, Regeneron Advisory, Seattle Genetics/Seagen, Immunogen Board Bayer, R Pharm, Fresenius Kabi, Miltenyi, 2seventy bio, Bayer and Loxo. R.E.O.C. is Vice-Chair for CPC and SGO and Chair of the DT Committee for NRG Oncology. The institution of P.H.T. received grants from Merck and GlaxoSmithKline. P.H.T. has stock in Immunon and was personally compensated for serving on advisory boards for Iovance, AstraZeneca, Verastem, GlaxoSmithKline, Seagen, Immunon, Immunogen, Mersana, Novocure, Zentalis, Caris, Merck and Caris. S.W. received personal payments and honoraria from Merck, GSK, AstraZeneca and Eisai. A.N.F. received honararia for speaking at the GOG Foundation, Endometrial Cancer Symposium and has also participated on the GSK advisory board while also serving as President of the Society of Gynecologic Oncology (unpaid position). M.A.P. received personal consulting fees from GSK, Tesaro, Merck, AstraZeneca, Immunogen, Seagen, Clovis Oncology and Kyropharma. M.A.P. also served in leadership roles for the GOG Foundation, SGO and FWC (uncompensated) alongside his role with NRG Oncology (compensated). C.A. received clinical trial funding to their institution (MSK) from AbbVie – MSK PI, GOG3005, Artios Pharma – International Coordinating Investigator & MSK PI, Artist; AstraZeneca – MSK PI, SOLO1/GOG 3004; National Coordinating Investigator & MSK PI, D081RC00001; ENGOT – ov46; AGO-OVAR 23; GOG-3025; Clovis – MSK PI, ARIEL 2 & 3; Genentech/Roche – MSK PI, GOG3015 (imAGYN050). C.A. participated in a virtual advisory board for Blueprint Medicine on 30 June 2021 (no consulting fee received) and also attended a virtual advisory board for Merck for Global Cervical and Ovarian Cancer on 10 July 2023. C.A. has ongoing commitments with AstraZeneca – AZ eVOLVE DMC 26 April 2023; AstraZeneca – Future Clinical Strategies for Endometrial Cancer Virtual Advisory Board 13 March 204 and Verastem – RAMP 301 Steering Committee, 6 March 2024. C.A. participated on a data safety monitoring board and advisory board for Blueprint Medicine – Virtual Advisory Board on 30 June 2021 (no consulting fee received); Merck – Global Cervical and Ovarian Cancer Virtual Advisory Board 10 July 2023; AstraZeneca – AZ eVOLVE DMC 26 April 2023 (ongoing); AstraZeneca – Future Clinical Strategies for Endometrial Cancer Virtual Advisory Board 13 March 2024; Verastem, RAMP 301 Steering Committee, 6 March 2024 (ongoing). C.A. serves on the Board of Directors for both the GOG Foundation and NRG Oncology (unpaid). The other authors declare no competing interests.
